BRIEF-Bellus Health says Kiacta did not meet primary efficacy endpoint in phase 3 study

Mon Jun 20, 2016 8:33am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

June 20 (Reuters) - Bellus Health Inc

* Announces top-line phase 3 results of kiacta for treatment of aa amyloidosis

* In study, Kiacta did not meet primary efficacy endpoint in slowing renal function decline

* Kiacta was shown to be safe and well tolerated over treatment periods of greater than 4 years

* Further analysis of data is ongoing. Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)